INSIGHTS ON DRUG DEVELOPMENT

• Evaluating CAR T-Cell Therapy Recruitment And Efficacy

  Learn about Organ-on-a-Chip technology and how it can be employed to assess the efficacy of CAR T-cell therapies against solid tumors.

• Biophysical Tools For Biotherapeutic Development

  Discover essential analytical techniques in biotherapeutics development, as well as explore ITC, DSC, and Rheology—powerful tools for understanding formulation, stability, and efficacy in drug development.

• Characterization And Impurity Profiling Of Combined Amylin And GLP-1 Analogs

  GLP-1 receptor agonists are transforming diabetes and weight loss treatment. Discover how to enable precise impurity analysis and characterization of complex, fatty acid-modified peptide therapeutics.

• Accelerating Method Development And Manufacturing Of GLP-1 Analogs

  Explore a streamlined LC-UV/MS workflow that empowers labs to meet rising GLP-1 drug demand with faster, more informed decisions that enhance compliance and impurity detection efficiency.

• Biologic Stability: A Thermofluor Screen For Rational Buffer Optimization

  9/23/2025

  Learn how thermal shift fluorimetry (thermofluor) can be used as a rapid, low-volume, and cost-effective technique to accelerate buffer optimization and enhance protein stability.

• Scaling Up Your E. Coli pDNA Process From Parameter Screening To Pilot Scale

  6/26/2025

  Discover a systematic approach to scalable plasmid DNA production using E. coli OneShot Top10, which features DOE-driven optimization and key insights for efficient biomanufacturing success.

• Evaluating Compound Toxicity Effects On Healthy Intestinal Organoids

  3/24/2025

  3D organoids enhance drug toxicity prediction and are crucial for anti-cancer drug development. Examine a method using 3D mouse intestinal organoids that aims to provide vital data on intestinal toxicity.

• Overcoming Challenges To High-Concentration Formulation Development

  3/25/2025

  Explore how the S-HiCon™ platform optimizes high-concentration therapeutic antibody formulations, overcoming stability and manufacturability challenges to deliver safe, effective therapies.

• Selecting A CDMO For Custom Activated PEGs

  1/27/2026

  Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.